Moderna drops after reporting trial for birth defect vaccine failed
dropped in after-hours trading Wednesday after it reported that its experimental vaccine for cytomegalovirus (CMV), which can cause birth defects, failed in a late-stage trial. The company is perhaps ...
Grail rises after announcing $325 million raise from Hims, others
, a cancer detection biotech, rose more than 20% after it announced that it raised $325 million from a slate of investors including . Grail sells a blood test that detects cancerous tumors early on. T...
Moderna rises on study suggesting COVID-19 shot enhances efficacy of cancer treatment
rose more than 5% on Monday after a new study showed that mRNA COVID-19 shots could enhance cancer immunotherapy. The results were presented by researchers from MD Anderson Cancer Center at the Europe...
.jpg?auto=compress%2Cformat&cs=srgb)
Hims & Hers rises after launching menopause and perimenopause treatments
ticked up after announcing on Wednesday that it will now offer treatments for perimenopause and menopause, a launch that has been eagerly anticipated by bullish retail investors. The company said it ...
String of acquisitions fuels biotech optimism
After nearly five years in the doldrums, a string of recent Big Pharma acquisition announcements has fueled a rally in biotech stocks. Because biotechs often have no revenues and use borrowed money to...
Lilly Endowment unloads about $600 million in Eli Lilly stock during early October
Lilly Endowment, a nonprofit associated with the founders of the pharmaceutical giant , has been on a selling spree this month. The insider has sold more than 1 million shares of Lilly in October in a...
Novo Nordisk to acquire liver disease drugmaker Akero Therapeutics for up to $5.2 billion
announced Thursdsay that it intends to acquire for up to $5.2 billion. Novo said it would pay $54 per share for Akero, a 15% premium to its $46.49 closing price in Wednesday, for a total of $4.7 bill...
CDC signs off on narrower Covid shot recommendation
Moderna slipped after the US Centers for Disease Control and Prevention announced on Monday that it is adopting a narrower recommendation for when COVID-19 booster shots are appropriate. The CDC’s rec...
Can pharma companies put tariff threats behind them?
For the past nine months, pharmaceutical companies have been paralyzed by uncertainty over the threat of US tariffs. It appears that regulatory haze is starting to clear. CEO Albert Bourla stood with ...
Novo says it will offer weight-loss pill via telehealth, Bloomberg reports
slipped after US head, David Moore, told Bloomberg that the company plans to sell its upcoming weight-loss pill through its current telehealth partners. The company’s weight-loss pill recently report...
Trump admin reportedly backs off on pharma tariffs
The Trump administration will not be imposing tariffs on pharmaceutical companies by the deadline it had initially given them, a White House official told STAT . Last week, President Trump announced o...
Tempus AI shares rise following executive order promoting AI to produce solutions for pediatric cancer
Shares of AI medical diagnostics company have shot up over 5% today. The stock is up over 150% for the year. Yesterday, President Trump signed an executive order to boost the use of AI to “produce me...
Pfizer reaches deal with Trump admin on drug pricing
rose Tuesday after it was announced that the drugmaker reached a deal with the Trump administration to lower its prices in the US. Pfizer will sell its drugs through Medicaid at lower prices, accordin...
Denmark revises GDP growth lower as key exporter Novo Nordisk struggles
Denmark’s economic growth has been revised lower amid a slump at the country’s largest company, . According to Statistics Denmark on Tuesday, the country’s second-quarter GDP growth was revised down t...
Pharma company Aurinia falls after FDA official uses LinkedIn to call out lupus drug
dropped on Monday after a Food and Drug Administration official criticized a method of evaluating drugs that was used to approve the company’s flagship lupus medication. George Tidmarsh, who has led t...
Merus surges after Genmab says it will acquire it for $8 billion
Danish biotech announced on Monday that it will acquire cancer startup in an all-cash deal worth about $8 billion. Genmab is buying Merus for $97 per share, a roughly 40% premium over its closing pri...
Why pharma stocks aren’t getting hit by new tariff threats
President Trump’s tariff threats don’t sting as much as they used to. On Thursday evening, Trump announced on Truth Social that starting on October 1 there will be a 100% tariff on patented, branded p...
UniQure surges after encouraging trial results for Huntington’s treatment
rose more than 150% in early trading Wednesday after it released trial results that showed its experimental gene therapy for Huntington’s disease slowed its progression by 75% after three years. The t...
Moderna rises after RFK Jr. vaccine panel’s less-draconian-than-expected Covid recommendation
rose more than 5% on Monday after a federal vaccine panel adopted a recommendation for the COVID-19 vaccine that is significantly narrower than before but not as draconian as some investors were prici...
Tempus AI jumps on FDA clearance of RNA-based testing tech
Shares of , an AI-powered medical diagnostics company, jumped on news that the FDA has granted 501(k) clearance for its Tempus xR IVD device. The RNA sequencing tool allows doctors to tailor therapies...